Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability.

Rosales C, Gillard BK, Xu B, Gotto AM Jr, Pownall HJ.

Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):47-54. doi: 10.14797/mdcj-15-1-47. Review.

2.

Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Jarrett KE, Lee C, De Giorgi M, Hurley A, Gillard BK, Doerfler AM, Li A, Pownall HJ, Bao G, Lagor WR.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):1997-2006. doi: 10.1161/ATVBAHA.118.311221.

PMID:
30026278
3.

Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins.

Gillard BK, Rosales C, Xu B, Gotto AM Jr, Pownall HJ.

J Clin Lipidol. 2018 Jul - Aug;12(4):849-856. doi: 10.1016/j.jacl.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29731282
4.

ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate.

Xu B, Gillard BK, Gotto AM Jr, Rosales C, Pownall HJ.

Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2260-2270. doi: 10.1161/ATVBAHA.117.310290. Epub 2017 Oct 26.

5.

Structural Stability of Streptococcal Serum Opacity Factor.

Yelamanchili D, Gillard BK, Gotto AM Jr, Pownall HJ, Rosales C.

Protein J. 2017 Jun;36(3):196-201. doi: 10.1007/s10930-017-9711-4.

6.

Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester.

Gillard BK, Bassett GR, Gotto AM Jr, Rosales C, Pownall HJ.

J Biol Chem. 2017 May 26;292(21):8864-8873. doi: 10.1074/jbc.M117.781963. Epub 2017 Apr 3.

7.

Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.

Jarrett KE, Lee CM, Yeh YH, Hsu RH, Gupta R, Zhang M, Rodriguez PJ, Lee CS, Gillard BK, Bissig KD, Pownall HJ, Martin JF, Bao G, Lagor WR.

Sci Rep. 2017 Mar 16;7:44624. doi: 10.1038/srep44624.

8.

Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism.

Pownall HJ, Rosales C, Gillard BK, Ferrari M.

Methodist Debakey Cardiovasc J. 2016 Sep;12(3):146-150. Review.

9.

Neo High-Density Lipoprotein Produced by the Streptococcal Serum Opacity Factor Activity against Human High-Density Lipoproteins Is Hepatically Removed via Dual Mechanisms.

Rodriguez PJ, Gillard BK, Barosh R, Gotto AM Jr, Rosales C, Pownall HJ.

Biochemistry. 2016 Oct 18;55(41):5845-5853. doi: 10.1021/acs.biochem.6b00946. Epub 2016 Oct 7.

PMID:
27662183
10.

Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo.

Yang Y, Rosales C, Gillard BK, Gotto AM Jr, Pownall HJ.

Biochim Biophys Acta. 2016 Nov;1861(11):1787-1795. doi: 10.1016/j.bbalip.2016.08.017. Epub 2016 Sep 2.

11.

Speciated High-Density Lipoprotein Biogenesis and Functionality.

Rosales C, Davidson WS, Gillard BK, Gotto AM Jr, Pownall HJ.

Curr Atheroscler Rep. 2016 May;18(5):25. doi: 10.1007/s11883-016-0572-7. Review.

PMID:
27005803
12.

Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM.

Murray SC, Gillard BK, Ludtke SJ, Pownall HJ.

Biophys J. 2016 Feb 23;110(4):810-6. doi: 10.1016/j.bpj.2015.10.028. Epub 2015 Dec 30.

13.

Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo.

Gillard BK, Rodriguez PJ, Fields DW, Raya JL, Lagor WR, Rosales C, Courtney HS, Gotto AM Jr, Pownall HJ.

Biochim Biophys Acta. 2016 Mar;1861(3):196-204. doi: 10.1016/j.bbalip.2015.12.006. Epub 2015 Dec 18.

14.

High-Density Lipoprotein Processing and Premature Cardiovascular Disease.

Rosales C, Gillard BK, Gotto AM Jr, Pownall HJ.

Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):181-5. doi: 10.14797/mdcj-11-3-181. Review.

15.

Alcohol: a nutrient with multiple salutary effects.

Pownall HJ, Rosales C, Gillard BK, Gotto AM Jr.

Nutrients. 2015 Mar 18;7(3):1992-2000. doi: 10.3390/nu7031992. Review.

16.

Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism.

Rosales C, Patel N, Gillard BK, Yelamanchili D, Yang Y, Courtney HS, Santos RD, Gotto AM Jr, Pownall HJ.

Biochemistry. 2015 Apr 14;54(14):2295-302. doi: 10.1021/bi501486z. Epub 2015 Apr 2.

17.

Setting the course for apoAII: a port in sight?

Pownall HJ, Gillard BK, Gotto AM Jr.

Clin Lipidol. 2013 Oct;8(5):551-560.

18.

Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome.

Vasudevan M, Tchoua U, Gillard BK, Jones PH, Ballantyne CM, Pownall HJ.

J Clin Lipidol. 2013 Nov-Dec;7(6):661-70. doi: 10.1016/j.jacl.2013.05.004. Epub 2013 May 25.

19.

Free cholesterol determines reassembled high-density lipoprotein phospholipid phase structure and stability.

Auton M, Bassett GR, Gillard BK, Pownall HJ.

Biochemistry. 2013 Jun 25;52(25):4324-30. doi: 10.1021/bi4006732. Epub 2013 Jun 14.

20.

Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.

Gillard BK, Raya JL, Ruiz-Esponda R, Iyer D, Coraza I, Balasubramanyam A, Pownall HJ.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1714-21. doi: 10.1161/ATVBAHA.113.301538. Epub 2013 May 2.

21.

Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.

Wooten JS, Nambi P, Gillard BK, Pownall HJ, Coraza I, Scott LW, Nambi V, Ballantyne CM, Balasubramanyam A.

Med Sci Sports Exerc. 2013 Jun;45(6):1043-50. doi: 10.1249/MSS.0b013e3182843961.

22.

Cholesterol determines and limits rHDL formation from human plasma apolipoprotein A-II and phospholipid membranes.

Bassett GR, Gillard BK, Pownall HJ.

Biochemistry. 2012 Oct 30;51(43):8627-35. doi: 10.1021/bi3011994. Epub 2012 Oct 16.

23.

Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo.

Rosales C, Tang D, Gillard BK, Courtney HS, Pownall HJ.

Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1834-41. doi: 10.1161/ATVBAHA.111.224360. Epub 2011 May 19.

24.

Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Tchoua U, Rosales C, Tang D, Gillard BK, Vaughan A, Lin HY, Courtney HS, Pownall HJ.

Lipids. 2010 Dec;45(12):1117-26. doi: 10.1007/s11745-010-3484-2. Epub 2010 Oct 24.

25.

Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol.

Gillard BK, Rosales C, Pillai BK, Lin HY, Courtney HS, Pownall HJ.

Biochemistry. 2010 Nov 16;49(45):9866-73. doi: 10.1021/bi101412m. Epub 2010 Oct 25.

26.

HDL superphospholipidation enhances key steps in reverse cholesterol transport.

Tchoua U, Gillard BK, Pownall HJ.

Atherosclerosis. 2010 Apr;209(2):430-5. doi: 10.1016/j.atherosclerosis.2009.10.002. Epub 2009 Oct 12.

27.

Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells.

Gillard BK, Lin HY, Massey JB, Pownall HJ.

Biochim Biophys Acta. 2009 Dec;1791(12):1125-32. doi: 10.1016/j.bbalip.2009.07.004. Epub 2009 Jul 25.

28.

Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.

Rosales C, Gillard BK, Courtney HS, Blanco-Vaca F, Pownall HJ.

Biochemistry. 2009 Aug 25;48(33):8070-6. doi: 10.1021/bi901087z.

29.

Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I.

Han M, Gillard BK, Courtney HS, Ward K, Rosales C, Khant H, Ludtke SJ, Pownall HJ.

Biochemistry. 2009 Feb 24;48(7):1481-7. doi: 10.1021/bi802287q.

30.

Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins.

Pownall HJ, Courtney HS, Gillard BK, Massey JB.

Chem Phys Lipids. 2008 Nov;156(1-2):45-51. doi: 10.1016/j.chemphyslip.2008.09.001. Epub 2008 Sep 16.

31.

Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption.

Gillard BK, Courtney HS, Massey JB, Pownall HJ.

Biochemistry. 2007 Nov 13;46(45):12968-78. Epub 2007 Oct 17.

32.

Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning.

Pownall HJ, Hosken BD, Gillard BK, Higgins CL, Lin HY, Massey JB.

Biochemistry. 2007 Jun 26;46(25):7449-59. Epub 2007 May 27.

PMID:
17530866
33.

Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2).

Gaubatz JW, Gillard BK, Massey JB, Hoogeveen RC, Huang M, Lloyd EE, Raya JL, Yang CY, Pownall HJ.

J Lipid Res. 2007 Feb;48(2):348-57. Epub 2006 Nov 13.

34.

N-Glycosylation is required for secretion-competent human plasma phospholipid transfer protein.

Qu SJ, Fan HZ, Gillard BK, Pownall HJ.

Protein J. 2006 Feb;25(2):167-73.

PMID:
16862459
35.

Plasma factors required for human apolipoprotein A-II dimerization.

Gillard BK, Chen YS, Gaubatz JW, Massey JB, Pownall HJ.

Biochemistry. 2005 Jan 18;44(2):471-9.

PMID:
15641771
36.

Decreased synthesis of glycosphingolipids in cells lacking vimentin intermediate filaments.

Gillard BK, Clement R, Colucci-Guyon E, Babinet C, Schwarzmann G, Taki T, Kasama T, Marcus DM.

Exp Cell Res. 1998 Aug 1;242(2):561-72.

PMID:
9683542
37.

Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways.

Gillard BK, Clement RG, Marcus DM.

Glycobiology. 1998 Sep;8(9):885-90.

PMID:
9675221
38.
39.

Biosynthesis of glycosphingolipids is reduced in the absence of a vimentin intermediate filament network.

Gillard BK, Thurmon LT, Harrell RG, Capetanaki Y, Saito M, Yu RK, Marcus DM.

J Cell Sci. 1994 Dec;107 ( Pt 12):3545-55.

40.

Variable subcellular localization of glycosphingolipids.

Gillard BK, Thurmon LT, Marcus DM.

Glycobiology. 1993 Feb;3(1):57-67.

PMID:
8448386
41.

Association of glycosphingolipids with intermediate filaments of mesenchymal, epithelial, glial, and muscle cells.

Gillard BK, Thurmon LT, Marcus DM.

Cell Motil Cytoskeleton. 1992;21(4):255-71.

PMID:
1628323
42.

Association of glycosphingolipids with intermediate filaments of human umbilical vein endothelial cells.

Gillard BK, Heath JP, Thurmon LT, Marcus DM.

Exp Cell Res. 1991 Feb;192(2):433-44.

PMID:
1899071
43.

Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids.

Gillard BK, Jones MA, Turner AA, Lewis DE, Marcus DM.

Arch Biochem Biophys. 1990 May 15;279(1):122-9.

PMID:
2110799
44.
45.

Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus.

Gillard BK, Thomas JW, Nell LJ, Marcus DM.

J Immunol. 1989 Jun 1;142(11):3826-32.

PMID:
2654294
46.

Structure of a ganglioside with Cad blood group antigen activity.

Gillard BK, Blanchard D, Bouhours JF, Cartron JP, van Kuik JA, Kamerling JP, Vliegenthart JF, Marcus DM.

Biochemistry. 1988 Jun 28;27(13):4601-6.

PMID:
3167001
47.

Glycosphingolipids of human umbilical vein endothelial cells and smooth muscle cells.

Gillard BK, Jones MA, Marcus DM.

Arch Biochem Biophys. 1987 Aug 1;256(2):435-45.

PMID:
3304165
48.
49.

Carbohydrate tolerance in cystic fibrosis is closely linked to pancreatic exocrine function.

Geffner ME, Lippe BM, Kaplan SA, Itami RM, Gillard BK, Levin SR, Taylor IL.

Pediatr Res. 1984 Nov;18(11):1107-11.

PMID:
6083538
50.

Insulin resistance in a young man with cystic fibrosis.

Geffner ME, Lippe BM, Itami RM, Kaplan SA, Gillard BK, Levin SR, Taylor IL.

Am J Dis Child. 1984 Jul;138(7):677-80.

PMID:
6375349

Supplemental Content

Loading ...
Support Center